The US dietary supplement industry’s success could make Food and Drug Administration regulations for its products vulnerable to challenge with the Supreme Court striking the Chevron doctrine of deference, particularly a rule considered the chief impediment to further growth.
“This is an industry that has been, that has been really concerned about FDA, about this drug preclusion provision, about...